Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novavax (DE:NVV1)
XETRA:NVV1
Novavax (NVV1) Stock Price & Analysis
7 Followers
NVV1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€3.33 - €23.93
Previous Close€14.99
Volume15.11K
Average Volume (3M)21.05K
Market Cap
€2.16B
Enterprise Value€1.92B
Total Cash (Recent Filing)$480.59M
Total Debt (Recent Filing)$229.33M
Price to Earnings (P/E)―
Beta3.04
Next Earnings
Aug 06, 2024EPS Estimate
€0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding140,403,554
10 Day Avg. Volume13,109
30 Day Avg. Volume21,054
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-1.98
Price to Sales (P/S)62.83
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.93
Enterprise Value/Gross Profit9.05
Enterprise Value/Ebitda-11.26
Forecast
1Y Price Target
€20.49Price Target Upside36.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Novavax News
PremiumCompany Announcements
Novavax Stockholders Elect Directors, Approve Executive PayBulls Say, Bears Say
Bulls Say
Financial RestructuringFinancially stronger going forward, with progress towards becoming a leaner and financially strong organization.
Market StrategyStrategic prioritization of key ex-US markets, including U.K. commercial market, resulting in delivery of ~$1B APAs through 2026.
Product DevelopmentNovavax' COVID-19 vaccine elicits broad and long-lived immune responses with a favorable reactogenicity profile.
Bears Say
Earnings4Q23 Top/Bottomline Miss, Lowered 1Q Guide Not a Huge Surprise
Market PositionContinuing to command a fringe share of the shrinking C-19 market
Product ChallengesMulti-dose format of Novavax vaccine could lead to pharmacy stock delays or avoidance, potentially resulting in inventory write-downs
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.04% Other Institutional Investors
98.96% Public Companies and
Individual Investors
NVV1 FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was €3.33 and its highest was €23.93 in the past 12 months.
What is Novavax’s market cap?
Currently, no data Available
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Aug 06, 2024 which is in 10 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on May 10, 2024. The company reported -€0.964 earnings per share for the quarter, beating the consensus estimate of -€0.977 by €0.013.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is €0.9.
How many shares outstanding does Novavax have?
Currently, no data Available
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -€0.964 in its last earnings report, beating expectations of -€0.977. Following the earnings report the stock price went up 99.831%.
Which hedge fund is a major shareholder of Novavax?
Among the largest hedge funds holding Novavax’s share is Coatue Management, LLC. It holds Novavax’s shares valued at 7M.
---
Novavax Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€20.49 (36.70% Upside)
€20.49 (36.70% Upside)
Blogger Sentiment
Bullish
DE:NVV1 Sentiment 85%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.26%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
---
NVV1 Company Deck
---
NVV1 Earnings Call
Q1 2024
0:00 / 0:00
---
NVV1 Stock 12 Month Forecast
Average Price Target
€20.49
▲(36.70% Upside)
Technical Analysis
Best Analysts Covering NVV1
1 Year
1 Year Success Rate
20/35 ratings generated profit
1 Year Average Return
+165.04%
reiterated a buy rating 3 months ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +165.04% per trade.
---